Clinical Trial Update: Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating pralatrexate with bendamustine and total-body irradiation followed by donor stem cell transplant for relapsed or refractor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Non-hodgkin Lymphoma

Drugs mentioned

• Folotyn (pralatrexate)
• Treanda (Bendamustine)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: RECRUITING